



**Australian Government**  
**Department of Health**  
Therapeutic Goods Administration

## Public Summary

<b>Summary for ARTG Entry:</b>	302620	Lymphodran Plus
<b>ARTG entry for</b>	Medicine Listed	
<b>Sponsor</b>	Bio Concepts Pty Ltd	
<b>Postal Address</b>	PO Box 190, Banyo, Brisbane, QLD, 4014 Australia	
<b>ARTG Start Date</b>	4/05/2018	
<b>Product Category</b>	Medicine	
<b>Status</b>	Active	
<b>Approval Area</b>	Listed Medicines	

### Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

### Products

#### 1 . Lymphodran Plus

<b>Product Type</b>	Single Medicine Product	<b>Effective Date</b>	17/02/2020
---------------------	-------------------------	-----------------------	------------

### Permitted Indications

- Antioxidant/Reduce free radicals formed in the body
- Maintain/support collagen formation
- Maintain/support general health and wellbeing
- Aid/assist/helps connective tissue production/formation
- Maintain/support cardiovascular system health
- Maintain/support blood capillary health
- Maintain/support immune system health
- Maintain/support healthy immune system function
- Helps prevent dietary (state vitamin/mineral/nutrient) deficiency in healthy individuals
- Aid/assist/helps synthesis of neurotransmitters
- Maintain/support wound healing in healthy individuals

### Indication Requirements

- Product presentation must not imply or refer to serious immunological diseases.
- Label statement: If symptoms persist, talk to your health professional.
- Label statement: [Vitamins/minerals/nutrients/dietary supplements] can only be of assistance if dietary intake is inadequate OR [Vitamins/minerals/nutrients/dietary supplements] should not replace a balanced diet (or words to that effect).
- Product presentation must not imply or refer to circulatory disorders/diseases/conditions e.g. thrombosis.
- Product presentation must not imply or refer to serious cardiovascular conditions.

### Standard Indications



**Australian Government**  
**Department of Health**  
Therapeutic Goods Administration

No Standard Indications included on Record

**Specific Indications**

No Specific Indications included on Record

**Warnings**

If symptoms persist, seek the advice of a healthcare professional.

Vitamins and minerals can only be of assistance if dietary intake is inadequate OR Vitamin and/or mineral supplements should not replace a balanced diet.

**Additional Product information**

**Pack Size/Poison information**

**Pack Size**

**Poison Schedule**

**Components**

**1 . Formulation 1**

**Dosage Form**                      Tablet, film coated

**Route of Administration**      Oral

**Visual Identification**

**Active Ingredients**

ascorbic acid	50 mg
bromelains	5.6 million PU
quercetin dihydrate	526.32 mg
Equivalent: quercetin	500 mg
rutoside	400 mg

**Other Ingredients (Excipients)**

calcium hydrogen phosphate dihydrate

Carnauba Wax

crospovidone

hypromellose

macrogol 400

magnesium stearate

maltodextrin

microcrystalline cellulose

povidone

silicon dioxide

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary